不可切除的晚期肝细胞癌的序贯经动脉化疗栓塞术
Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma.
作者信息
Jaeger H J, Mehring U M, Castañeda F, Hasse F, Blumhardt G, Loehlein D, Mathias K D
机构信息
Department of Diagnostic Radiology, City Hospital Dortmund, Germany.
出版信息
Cardiovasc Intervent Radiol. 1996 Nov-Dec;19(6):388-96. doi: 10.1007/BF02577625.
PURPOSE
The aim of this prospective study was to evaluate the feasibility, safety, and efficacy of sequential transarterial chemoembolization (TACE) for patients with unresectable advanced hepatocellular carcinoma (HCC).
METHODS
Twenty-one consecutive patients with unresectable T3 and T4 HCC were treated by sequential TACE (median time interval between treatments 7 weeks) up to six times with an emulsion of lipiodol, epirubicin, and cisplatin. All TACE procedures were performed as unilobar or whole-liver chemoembolization.
RESULTS
An average of 3.9 TACE procedures were performed per patient. One primary and two secondary technical failures occurred. No procedural death was observed. After exclusion of the patient with the primary technical failure and 3 patients with extrahepatic disease, the survival rates for the remaining 17 patients at 6, 12, 18, and 24 months were 70.6%, 52.9%, 44.1%, and 33.1%, respectively.
CONCLUSION
Sequential TACE is a safe procedure in patients with unresectable advanced HCC and feasible in most cases. It seems to prolong the survival time compared with historical series of untreated patients.
目的
本前瞻性研究旨在评估序贯经动脉化疗栓塞术（TACE）对不可切除的晚期肝细胞癌（HCC）患者的可行性、安全性和疗效。
方法
连续21例不可切除的T3和T4期HCC患者接受序贯TACE治疗（治疗间隔时间中位数为7周），最多进行6次，使用碘油、表柔比星和顺铂乳剂。所有TACE手术均作为单叶或全肝化疗栓塞进行。
结果
每位患者平均进行3.9次TACE手术。发生1例原发性和2例继发性技术失败。未观察到手术死亡。排除原发性技术失败患者和3例肝外疾病患者后，其余17例患者在6、12、18和24个月时的生存率分别为70.6%、52.9%、44.1%和33.1%。
结论
序贯TACE对不可切除的晚期HCC患者是一种安全的手术，在大多数情况下可行。与未治疗患者的历史系列相比，似乎能延长生存时间。
Zotero 插件